FIBROBLAST GROWTH FACTOR 23 IS A NOVEL BIOMARKER FOR CARDIAC FUNCTION IN HEART FAILURE PATIENTS
Miki Imazu(National Cerebral and Cardiovascular Center), Masafumi Kitakaze(Hanwa Memorial Hospital), Akira Funada(National Cerebral and Cardiovascular Center), Hiroshi Asanuma(Meiji University of Integrative Medicine), Hideaki Kanzaki(National Cerebral and Cardiovascular Center), Toshihisa Anzai(Hokkaido University), Hiroyuki Takahama(Tohoku University), Takuya Hasegawa(National Cerebral and Cardiovascular Center), Takahiro Ohara(Tohoku Medical and Pharmaceutical University), Atsushi Nakano(National Cerebral and Cardiovascular Center), Masanori Asakura(National Cerebral and Cardiovascular Center), Yasuo Sugano(keiyu Hospital)
Cited by 0
Related Papers
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: Metalloproteinase inhibitors as a new therapy
|Nature Medicine|2002|722
Right Ventricular Function in Heart Failure With Preserved Ejection Fraction
|Circulation|2014|456